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Hydroxysteroid dehydrogenases (HSDHs), mainly obtained from bacterial 
sources, have been widely employed for the regio- and stereoselective 
oxidoreduction of the hydroxyl-keto groups of steroids, bile acids and their 
derivatives. In particular they might be suitable biocatalysts for the industrial 
synthesis of bile acids derivatives of pharmacological interest such as 
ursodeoxycholic acid (UDCA; 3α,7β-dihydroxy-5β-cholan-24-oic acid). 
 
Aim of this work was i) to investigate a new enzymatic process for the synthesis 
of UDCA; ii) to develop new cofactor regeneration systems to be coupled to 
HSDHs-catalyzed reactions; iii) to clone and overexpress in E. coli new HSDHs 
suitable for the modification of bile acids up to an industrial level. 
 
Specifically, the preparative-scale HSDHs-catalyzed one-pot enzymatic 
synthesis of 12-ketoursodeoxycholic acid (3 ,7 -dihydroxy-12-oxo-5 -
cholanoic acid), a key intermediate for the synthesis of ursodeoxycholic acid, 
from cholic acid has been investigated. This goal has been achieved by 
alternating oxidative and reductive steps in a one-pot system and employing 
HSDHs with different cofactor specificity. To provide the necessary driving 
force to opposite reactions (i.e., oxidation and reduction) acting concurrently on 
different sites of the same substrate molecule, suitable cofactor regeneration 
systems were coupled to these reactions. However, due to a limited cofactor 
specificity of some of the enzymes used, an undesired reaction equilibrium was 
established resulting in by-products formation. This problem was overcome by 
uncoupling the oxidative and reductive biocatalysts (Paper I).  
 
Moreover, a new laccase/mediator system for NAD(P)
+
 cofactor regeneration in 
HSDHs-catalyzed oxidations has been developed. This system has been 










demonstrating to be very efficient, to have high stability, to tolerate solvents, 
and to be simple to employ (Paper II). 
 
Finally, NADPH-dependent 7α- and 7β-hydroxysteroid dehydrogenases (7α-
HSDH and 7β-HSDH) from Clostridium absonum were cloned and 




characterized from a functional and a kinetic point of view, demonstrating that 
both of them, in suitable bioconversion conditions, could be promising 
candidates for further applications in the epimerization reaction of bile acids at 
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Industrial Biotechnology, i.e., the application of biotechnology for the 
processing and production of chemicals, materials, and energy, is having an 
increasingly important role in the development of a sustainable, bio-based 
economy at a European level. Beside biotechnological applications in sectors 
such as food and feed, paper and pulp, textiles and energy, easy access to 
building blocks and materials, that were only affordable before by laborious 
routes or not at all, could be provided to the chemical industry by Industrial 
Biotechnology processes (Schmid A et al. 2001).  
Biocatalysis, in the framework of Industrial Biotechnology, is considered a key 
component for the development of a sustainable chemistry in Europe by the 
European Commission, CEFIC and Biotech Industries Association 
(http://www.suschem.org/). Biocatalysis involves the use of enzymes' special 
ability to solve problems in the pharmaceutical field and in fine chemistry. 
Enzymes are very attractive for industrial purposes because of their high 




) and their extraordinary selectivity. Moreover, 
enzymes can be used under mild conditions (temperature around 30°C at 
ambient pressure) and in aqueous systems, thus limiting the use of organic 
solvents and reducing the environmental impact. Biocatalysis can also help the 
shortening of synthetic routes, avoiding protection group chemistry, and reduce 
by-products formation. This may result effective in lowering operation time and 
costs as well (Hollmann F et al. 2011). 
In recent years, biocatalysis has gained significant attention thanks to the fact 
that the number of available enzymes is continuously increasing. Moreover, 
protein engineering, by improving enzyme properties, allows to overcome 
limitations for synthetic applications of the enzymes found in Nature. 
Up to now, more than 100 industrial enzymatic processes have been introduced 
(Strohmeier GA et al. 2011). Large-scale examples include the preparation of 
semisynthetic penicillins catalyzed by penicillin amidases and the exploitation 
of nitrile hydratase to catalyze the hydration of acrylonitrile into acrylamide 
(Zaks A et al. 2001). 
The development of a biocatalytic process requires the identification and, in 
some cases, the improvement, of one or more suitable biocatalysts, and the set-
up of an economically feasible bioconversion. Therefore, the input of many 
different specialists, such as biochemists, microbiologists, organic chemists and 





biocatalytic process depends on several factors, first of all the availability of an 
highly efficient and stable biocatalyst. To limit enzyme consumption, some 
biocatalysts are used in immobilized form as heterogeneous catalysts that can be 
recovered and reused. However, homogeneous processes that make use of 
suspended cells or recombinant enzymes that are sufficiently inexpensive to 
permit single use have been developed as well. 
Many biocatalytic processes are based on bioconversions catalyzed by cofactor-
independent enzymes, such as hydrolases and isomerases. Specifically, 
hydrolytic enzymes, e.g., esterases, lipases and proteases, have been widely 
applied to the preparation of enantiopure compounds from racemic or 
diastereomeric mixtures. These enzymes are often active even in anhydrous 
organic solvents, thus allowing their exploitation not only in the natural reaction 
direction, i.e., hydrolysis, but also in the reverse synthetic direction by means of 
either reverse hydrolysis or transesterification mechanisms. 
However, many synthetically practical enzymatic reactions require cofactors, 
whose regeneration from its reaction by-product is necessary in order to develop 
an economically and industrially feasible process. For example, the cost of 
NAD
+
 is of around 1,500 euros per kilogram and that of NADP
+
 around 6,000 
euros per kilogram. The reduced forms NADH and NADPH are considerably 
more expensive than the oxidized ones. Nevertheless, in combination with 
suitable regeneration systems, various cofactor-dependent reactions have been 
applied on preparative or industrial scale. 
In this respect, enzyme belonging to the oxidoreductases class, such as 
dehydrogenases, monooxygenases, dioxygenases, oxidases, peroxidases, are 
currently receiving increasing interest for their synthetic application at an 
industrial level. The reactions catalyzed by oxidoreductases are numerous and 
comprise oxidation of hydroxyl, aldehyde and keto groups, oxidation of primary 
and secondary amines, hydroxylation of aromatic or non-activated carbon 
atoms, dehydrogenation of carbon-carbon single bonds, heteroatom 
oxygenation, Baeyer-Villiger oxidation, and double bond epoxidation. 
Reduction reaction of aldehydes, ketones, carboxylic acids and double and triple 
carbon-carbon bonds can be catalyzed as well. A wide array of cofactors may be 
involved in oxidoreductases-catalyzed reactions, such as NAD(P)
+
, cytochrome, 
quinone or similar compounds, and flavin. Synthetic applications of isolated 
NAD(P)H-dependent oxidoreductases, e.g., dehydrogenases and enoate 
reductases, are most likely to be developed thanks to the existence of different 





This Thesis deals with the biocatalytic application of a selected class of 
NAD(P)H-dependent oxidoreductases, hydroxysteroid dehydrogenases. 
The work done during this Ph.D was performed at the ICRM-CNR (Milano, 
Italy) and supported by Prodotti Chimici e Alimentari S.p.A (PCA) (Basaluzzo 
(AL), Italy), a world leader company in the production of bile acids for 
pharmacological applications. Specifically, PCA produces ursodeoxycholic acid 
(UDCA; 3α,7β-dihydroxy-5β-cholan-24-oic acid), the first-choice drug used in 
the treatment of cholesterol gallstones, by a ton-scale chemical synthesis. 
However, this route is not completely satisfactory because of the lengthy 
protocol, the low yields and the use of polluting substances. The biocatalytic 
routes herein investigated, using enzymes such as hydroxysteroid 
dehydrogenases (HSDHs), could be valid alternatives in order to shorten the 
synthesis, increase the yield of UDCA and reduce the environmental impact. 
The work described in this Thesis is helping PCA in introducing biocatalytic 
methods in the synthesis of UDCA (and possibly in that of other bile acid 
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5 Bile acids 
Structure and biosynthesis of bile acids 
 
Bile acids are polycyclic molecules belonging to the steroids family and 
characterized by the presence of a short aliphatic side chain with a terminal 
carboxylate group linked to the rigid steroid nucleus (Fig. 1). The latter is 
formed by a cyclopentane ring (designated as D ring) fused to three six-member 
rings (designated as A, B and C rings). In higher vertebrates, because the A and 
B rings are fused in a cis configuration, the steroid nucleus is curved and 
presents a convex hydrophobic surface (face ) and a concave hydrophilic 
surface (face ). This, coupled to the presence of the negatively charged side 
chain, gives a strong amphiphilic nature to these molecules, from which the 
well-known detergent properties arise (Mukhopadhyay S and Maitra U 2004).  
 
 
Figure 1. Structure of bile acids (specifically cholic acid). a) chemical structure, b) 
tridimensional structure (Mukhopadhyay S and Maitra U 2004). 
 
Primary bile acids, i.e. cholic (CA; 3α,7α,12α-trihydroxy-5β-cholan-24-oic 
acid) and chenodeoxycholic (CDCA; 3α,7α-dihydroxy-5β-cholan-24-oic acid), 
are, together with cholesterol, phospholipids and bilirubin, the principal 
constituents of bile. They are synthesized in the liver from cholesterol, secreted 
in the bile canaliculi and subsequently stored in the gall bladder where they are 
concentrated during the interdigestive period.   
The hepatic synthesis of bile acids accounts for the majority of cholesterol 
breakdown in the body. In humans, ca. 500 mg of cholesterol is converted to 
bile acids every day (Thomas C et al. 2008). 
The biosynthetic pathway of CA and CDCA, summarized in Figure 2, is a 
multienzymatic process which results in both the modification of the ring 














































Cholic acid Chenodeoxycholic acid
 
 Figure 2. Primary bile acids biosynthesis.  
i. 7α-Hydroxylation (rate limiting 
step) 





iv. Side chain oxidation to C27 acid 
v. Saturation to A/B cis 
vi. Reduction of 3-oxo to 7α-OH 
vii. Oxidative cleavage of side 




7 Bile acids 
In this pathway, two different hydroxylations occur, catalyzed by microsomal 
mixed function oxidases. The first of these hydroxylations, catalyzed by a 
cholesterol 7α-hydroxylase at C-7, is the rate limiting step and control the whole 
pathway. The second hydroxylation reaction, at C-12, leads to the formation of 
the cholic acid backbone. Finally, the dehydrogenation and the subsequent 
reduction of the hydroxyl group at C-3 inverts its configuration and combines 
the rings A and B in a cis-type configuration. (Mukhopadhyay S and Maitra U 
2004).  
 
Before being secreted into the bile, bile acids in the liver are usually conjugated 
via an amide bond to the amino acids glycine and taurine. This process makes 
bile acids impermeable to cell membranes and permits high concentrations to 
persist in bile and intestinal content. The conjugates of cholic acid with glycine 
and taurine are called glycocholate and taurocholate, respectively. 
After food ingestion, release of cholecystokinin from the duodenum stimulates 
the gall bladder to contract, causing bile to flow into the duodenum, where it 
contributes to the solubilization and digestion of lipid-soluble nutrients. Bile 
acids are then absorbed by high-affinity active transport from the terminal 
ileum, complexed with plasma proteins in the bloodstream, and transported 
back to the liver via the portal vein - a process termed enterohepatic circulation. 
The liver extracts bile acids with great avidity and reconjugates deconjugated 
bile acids before resecreting them into the bile, thus completing enterohepatic 
circulation. Absorption of bile acids from the distal intestine leads to the 
accumulation of a large mass of bile acid molecules, termed the bile acid pool, 
which is about 2 to 3 g in weight in adults. Therefore, bile acid synthesis, 
which, as reported above, averages about 0.5 g/d, is “amplified” by the 
enterohepatic cycling of bile acids. (Hofmann AF 1999a, Ridlon JM et al. 
2006). 
Bile acids that are not reabsorbed in the small intestine (about 400-800 mg/d) 
pass into the large intestine where they encounter populations of facultative and 
strictly anaerobic bacteria. The intestinal flora consists mainly of 
microorganisms belonging to the families Lactobacillaceae and Bacteroidaceae, 
and to a lesser extent, of microorganisms such as Escherichia coli, coliforms 
and Clostridia. These intestinal bacteria express enzymes that transform primary 
bile acids into different derivatives, called secondary bile acids. The relationship 
between bile acids and intestinal microorganisms is a two-way process, that is, 




8 Bile acids 
Bile acids modifications by intestinal bacteria include deconjugations, 
oxidations/reductions of hydroxyl groups at C-3, C-7, and C-12, epimerizations 
of hydroxy groups and 7α/β-dehydroxylations (Fig. 3). Deconjugations and 
7α/β-dehydroxylations of bile acids increase their hydrophobicity and their pKa, 
thereby permitting their recovery via passive absorption across the colonic 
epithelium. In this way intestinal bacteria contribute to the recovery of bile salts 
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Figure 3. Bacterial bile salt biotransformations in the human intestinal tract. BSH, bile 
salt hydrolase; HSDH, hydroxysteroid dehydrogenase. 
 
Deconjugation, i.e. the enzymatic hydrolysis of the C-24 N-acyl amide bond 











9 Bile acids 
hydrolases (BSHs), enzymes belonging to the choloylglycine hydrolase family 
(EC 3.5.1.24). These enzymes have been isolated and/or characterized from 
several genera of intestinal bacteria, such as Bacteroides, Lactobacillus, 
Clostridium and Bifidobacterium. 
Oxidations and epimerizations of hydroxyl groups at C-3, C-7, and C-12 are 
catalyzed by hydroxysteroid dehydrogenases (HSDHs), a group of 
oxidoreductases belonging to the short chain dehydrogenase/reductase (SDR) 
superfamily (Kavanagh et al. 2008). Epimerization, i.e. the reversible change in 
stereochemistry from α to β configuration (or vice versa) through a keto 
intermediate, requires the concerted effort of two position-specific, 
stereochemically distinct HSDHs of intraspecies or interspecies origin. These 
enzymes will be further discussed in the following. 
Both deconjugation and epimerization of hydroxyl groups decrease toxicity of 
bile acids and they could represent strategies acquired by intestinal bacteria to 
counteract bile salt toxicity (Ridlon JM et al. 2006).  
Unlike bile acid oxidation and epimerization, 7α/β dehydroxylation appears 
limited to deconjugated bile acids. In fact, removal of glycine/taurine from bile 
acid conjugates by BSH enzymes is a prerequisite for 7α/β -dehydroxylation by 
intestinal bacteria. 7α-dehydroxylation is the most quantitatively important 
bacterial bile salt biotransformation in the human colon. Lithocholic acid (LA, 
3α-hydroxy-5β-cholan-24-oic acid) and deoxycholic acid (DCA, 3α,12α-
dihydroxy-5β-cholan-24-oic acid), formed from CA and CDCA 
dehydroxylation, respectively, are indeed the most abundant bile acids in human 
feces. Removal of the 7-hydroxy group proceeds through a multi-step 
biochemical pathway. This pathway has been extensively investigated by 
Hylemon and coworkers who reported that genes codifying for the enzymes 
involved in the 7α-dehydroxylation route are part of a policystronic bile acid 
inducible operon in Clostridium sp. strain TO-931, Clostridium scindens VPI 
12708, and Clostridium hylemonae (Ridlon JM et al. 2010, Wells JE and 
Hylemon PB 2000, Mallonee DH and Hylemon PB  1996). 
 
 
Physiological functions of bile acids 
 
Physiological functions of bile acids have been well established.  
First of all, bile acids promote the elimination of the excess of cholesterol, bile 




10 Bile acids 
Moreover, micellar solubilization of cholesterol in bile enables cholesterol to 
move from the hepatocytes to the intestinal lumen, and ultimately to be 
eliminated via the fecal route(Hofmann AF 1999a). 
In addition to the homeostatic function on cholesterol, bile acids play an 
important role in the solubilization and transport of lipids in the digestive 
process. In fact, the surface area of fat particles can be greatly increased through 
the formation of mixed micelles, thus making them more widely available to the 
degradative action of lipases. Moreover, mixed micelles of bile acids are 
responsible for the solubilization and absorption of fat-soluble vitamins, such as 
vitamin E (Mukhopadhyay S and Maitra U 2004, Traber MG 1996).  Bile acids 
contribute to the intestinal absorption of many dietary lipids also by activating 
the pancreatic lipase BAL (bile acid activated lipase), which catalyzes the 
conversion of triglycerides in glycerol and fatty acids (Wang CS et al. 1999, 
Terzyan S et al. 2000).  
In addition to lipid digestion, bile salts may be involved in other processes. For 
example, it has been recently reported that conjugated bile acids affect the 
digestion and assimilation of dietary proteins by accelerating the hydrolysis 
catalyzed by pancreatic proteases, such as trypsin and chymotrypsin. The 
related mechanism is still unknown, but it has been hypothesized that binding of 
bile acids to hydrophobic pocket(s) of the proteases may destabilize their 
structure, making additional interior domains of the dietary protein available for 
luminal endoprotease action (Gass J et al. 2007). 
Other physiological functions of bile acids include stimulation of bile flow and 
of biliary phospholipid secretion. Bile acids are actively transported into the 
semipermeable biliary canaliculi, where they reach high concentration and 
induce bile flow by means of their osmotic properties. The presence of 
phospholipids in bile results in a greater fraction of bile acids existing in the 
form of mixed micelles and a lower monomer concentration of bile acids, 
thereby preventing bile acids from damaging the bile duct epithelium (Hofmann 
AF 1999a and Hofmann AF 1999b). 
Finally, bile acids have recently been shown as versatile signaling molecules 
endowed with systemic endocrine functions. It has been demonstrated that they 
are ligands for G-protein-coupled receptors such as TGR5 and also modulate 
several nuclear hormone receptors including farnesoid X receptor (FXR) and 
pregnane X receptor (PXR). Through activation of these diverse signaling 
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and enterohepatic recirculation, but also triglyceride, cholesterol, energy and 
glucose homeostasis (Thomas C et al. 2008, Staudinger JL et al. 2001). 
 
Bile acids applications  
 
Currently, the main applications of bile acids are in the field of pharmacology, 
in particular they are used in the treatment of bile acid deficiencies, some liver 
diseases, and in the dissolution of cholesterol gallstones. 
There are two main rationales for administering bile acids in therapy. The first 
is bile acids replacement, where the aim is to correct a deficiency of bile acids 
caused by defective biosynthesis (inborn errors of metabolism) or defective 
intestinal conservation (short bowel syndrome). The second is bile acids 
displacement where the aim is to change the composition of the circulating bile 
acids without any great change in tissue concentrations or secretion. This is 
achieved in the treatment of cholestatic liver disease and cholesterol gallstone 
disease (Hofmann AF and Hagey LR 2008, Hofmann AF 2009). 
Cholesterol gallstones are hard, stones-like formations, ranging in size from a 
few millimeters to several centimeters, that can accumulate in the gall bladder. 
Most of these gallstones are produced in the presence of a cholesterol-saturated 
bile, a factor favoring the precipitation of cholesterol itself, first with the 
formation of minute crystals and then as clusters of larger and larger size. The 
prevalence of cholesterol gallstones disease in adults ranges from 10% to 15% 
(Di Ciaula A et al. 2010). 
The bile acids-mediated dissolution was introduced in the early '70s, the drug of 
first choice being ursodeoxycholic acid (UDCA, 3α,7β-dihydroxy-5β-cholan-
24-oic acid, Fig. 4). UDCA is the major bile acid in nutrias, bears, and beavers, 
while it is present only in small amount in human bile (3-4 %). UDCA appears 
to be almost as effective as its enantiomer chenodeoxycholic acid (CDCA), but 
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The best indication of UDCA in cholesterol gallstones dissolution therapy is 
represented by symptomatic patients with small (< 5 mm), mobile, not calcified, 
cholesterol-enriched (i.e., more than 80%) gallstones, and contained within a 
functioning gall bladder with a patent cystic duct. This event comprises about 
15 % of patients with gallstones and avoids the removal of the gallstones by 
surgical treatment. 
The mechanisms by which this effect occurs are many: decreasing secretion of 
cholesterol into the bile via a reduction in intestinal absorption and hepatic 
synthesis of cholesterol itself, increasing the total pool of bile acids that favor 
the micellar solubilization of cholesterol, forming a liquid-crystalline 
mesophase which allows a solubilization of cholesterol superior than that 
achieved in the equilibrium phase (Di Ciaula A et al. 2010, Jain UK et al. 1992).  
 
UDCA has been proven to be very effective in the treatment of many other 
cholestatic diseases. In fact, it is currently used in the standard treatment of 
primary biliary cirrhosis (PBC), a chronic autoimmune inflammatory disease of 
the liver with a striking female preponderance (Bhandari BM et al 2011). In 
PBC, treatment with UDCA improves liver tests and increases the time interval 
to liver transplantation (Hofmann AF and Hagey LR 2008). Moreover, UDCA 
is the most studied drug for the treatment of primary sclerosing cholangitis 
(PSC), a chronic cholestatic disease characterized by inflammation and 
progressive obliterative fibrosis of the intra and ⁄or extra-hepatic biliary tree 
which leads to bile stasis and hepatic fibrosis. Up to now, the efficacy of UDCA 
in PSC treatment is still controversial, some clinical trials suggesting that 
UDCA only slows disease progression (Triantos CK et al. 2011, Hofmann AF 
and Hagey LR 2008). On the contrary, UDCA is clearly useful in the syndrome 
of cholestatic disease of pregnancy which is likely to be caused by a defect in 
canalicular transport (Glantz A et al. 2005). In cholestasis of pregnancy, UDCA 
has been shown to improve liver tests and fetal outcome (Hofmann AF and 
Hagey LR 2008).  
 
Also in the case of cholestatic diseases, UDCA positive effects may be the 
result of its multiple mechanisms of action. For example, while the high 
concentration of citotoxic bile acids, such as CDCA, can differentially induce 
either necrosis or apoptosis in cholestatic diseases, UDCA halts apoptosis by 
preventing the formation of mitochondrial pores, membrane recruitment of 
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intracellular bile acids level and decrease bile acids citotoxicity by inducing 
changes in the expression of metabolizing enzymes and transporters which 
result, for example, in a decrease in bile acids synthesis, in an increase in bile 
acid hydroxylation and in an improved renal excretion. Its capability to 
positively modulate ductular bile flow helps to preserve the integrity of bile 
ducts and UDCA also prevents the endocytic internalization of canalicular 
export pumps involved in bile flow generation, a common feature in cholestasis.  
 
Finally, UDCA has immunomodulatory properties that limit the exacerbated 
immunological response occurring in autoimmune cholestatic diseases by 
counteracting the overexpression of MHC antigens and perhaps by limiting the 
production of cytokines by immunocompetent cells (Roma MG et al. 2011). 
Additionally, it has also been recently demonstrated that UDCA protects liver 
cells from the immune reactions caused by the transplantation of hematopoietic 
cells (McDonald GB 2006). Potential applications of UDCA and of its 
derivatives as a neuroprotectant in Huntington's disease and Alzheimer's disease 
have been suggested as well (Sharma R et al. 2011). 
Moreover, evidences from experimental animal models and human studies 
suggest that UDCA exerts chemopreventive activity against colorectal 
carcinogenesis and, in particular, it has been shown that it may inhibit tumor 
development in some experimental genetic and chemical models of intestinal 
tumorigenesis (Serfatya L et al. 2010). 
 
UDCA is currently produced by a chemical synthesis using as starting substrate 
cholic acid, which is found in large quantities in the bile of mammals. 
The hydroxy groups at C-3, C-7 and C-12 have different reactivity and therefore 
it is possible to catalyze regiospecific oxidation/reduction and acylation 
reactions. The reduction of the oxo-derivatives with NaBH4 leads preferentially 
to the formation of axial hydroxy group, while the use of sodium alkoxides, 
e.g., sodium methoxide, in the presence of hydrogenation catalysts leads mainly 
to equatorial hydroxy groups.  
 
Industrial-scale production of UDCA is carried out by the seven-steps chemical 
process shown in Figure 5 (Hofmann AF 1963; Samuelsson B 1960). However, 
the yields are limited to about 30% and the stereo- and regioselectivity is never 
absolute, several steps of purification and crystallization being required to 
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synthesis involves the use of highly polluting and toxic substances such as 
CrO3, pyridine and methanol, the residues of which must be completely 
eliminated from the final product. 
To overcome the low yields of the above mentioned process, several changes to 
the method have been proposed, such as the use of tert-amyl alcohol and 
potassium instead of methanol and sodium (Batta AK et al. 1991). According to 
this procedure, a product with a 90% purity degree and a yield of 95% can be 
recovered, but only after multiple steps of crystallization with ethyl acetate to 
remove the co-product chenodeoxycholic acid.   
Many approaches have been also proposed in order to obtain a safer process, 
such as the indirect electrooxidation of chenodeoxycholic acid to 7-
ketolithocholic acid (7KLCA, 3α-hydroxy-7-oxo-5β-cholan-24-oic acid) (Zhao 
H et al 2010).   
 
Alternative synthetic pathways including biotransformation steps, either by 
whole cells or isolated enzymes, will be presented and discussed in the 






















































































16 Bile acids 
Recently, bile acids-controlled signaling pathways have become the source of 
promising novel drug targets thanks to the newly discovered activity of these 
compounds as ligands of the FXR, PXR, and TGR5 receptors. Both natural bile 
acids and semisynthetic derivatives are currently under investigation for the 
treatment of metabolic disorder, hepatic disease, diabetes, and obesity through 
the activation of FXR or TGR5 receptors. (Thomas C. et al. 2008).  
 
Moreover, recent studies have revealed that the PXR receptor can function as a 
master regulator in the control of the expression of drug-metabolizing enzymes, 
such as enzymes of the cytochrome P450 3A (CYP3A) family, and of members 
of the drug transporter family, including multiple drug resistance 1 (MDR1). 
Therefore, PXR downregulation by bile acids analogues could be a novel 
therapeutic approach for the augmentation of sensitivity to anticancer agents or 
to overcome resistance to them, e.g., in the treatment of endometrial cancer 
(Masuyama H et al 2007). 
 
In addition to pharmaceutical applications, several applications of bile acid as 
"building blocks" for the construction of chiral artificial receptors and 
supramolecular hosts for molecular recognition have been proposed as well 
(Tamminem J and Kolehmainen E 2001). Bile salts are used for the structural 
rigidity of the steroid skeleton, which allows the formation of stable cavities, 
and because both hydroxyl groups and the side-chain carboxylate can be readily 
derivatized. Moreover, the cis A/B junction allows ring A of bile acids to bend 
inward and produce a concave curvature where all of the OH groups line on the 
inside (Mukhopadhyay S and Maitra U 2004). Some examples of artificial 
receptors are the anion receptor characterized by a marked selectivity for the 
fluoride ion (Davis AP et al. 1997), and the porphyrin conjugated cyclocholate 
selective for organic-soluble glycoside (Davis AP and Wareham RS 1999), 





























































Figure 6. a) Acyclic cholic acid-based receptor for anions (Mukhopadhyay S and 
Maitra U 2004); b) porphyrin-conjugated cyclocholate; c) titanium nanotubes made 
from hydrogel derived from tripodal cholamide gelator (Gundiah G et al 2003). 
 
Bile acids have also been used for the optical resolution of several classes of 
racemic organic compounds by forming crystalline enantioselective inclusion 
complexes with organic compounds (Bortolini O et al. 2005). 
A new and interesting application of bile acids is in the chemical synthesis of 
polymers which can be used for drug delivery, as gelificator agents or for other 
applications such as chromatographic supports and photoresists. (Ropponem J 
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gels in aqueous solutions and esterification of bile acids with different organic 
substances allows to change the physical characteristics of the gel. Hydrogels 
derived from bile acids are of considerable interest due to their excellent water-
holding ability. Dye-intercalation studies on gels show that they could be 
potential materials for drug delivery. It is noteworthy that these hydrogels are 
thermoreversible and biodegradable, unlike traditional polymeric gels 
(Mukhopadhyay S and Maitra U 2004). 
Additionally, these gels can be used as templates to prepare inorganic nanotubes 
as shown in Figure 6c. (Gundiah G et al 2003).  
Finally, the high specificity and capacity of the bile acid transport systems 
during the enterohepatic circulation forms the basis of the current research 
efforts to elaborate drug-bile acid conjugates for specific drug targeting to the 
liver and for improving the intestinal absorption of poorly absorbed or non-
absorbed drugs, e.g., peptides. For example, Kramer and Wess joined various 
drug molecules to positions 3, 7, and/or 12 in the steroid nucleus via linker 
moieties of different functionality, length, and polarity. One of these conjugates 
is shown in Figure 7, where oxaprolylpeptide, a drug for liver fibrosis, has been 
conjugated to a cholic acid derivative. This conjugate showed a greatly 
improved ileal absorption compared to the parent drug (Tamminem J and 
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Hydroxysteroid dehydrogenases 
 
Hydroxysteroid dehydrogenases (HSDHs) are NAD(P)H-dependent enzymes 
which catalyze the oxidation/reduction of hydroxyl groups of steroids or bile 
acids in vivo (Ridlon JM et al. 2006). They belong to the short chain 
dehydrogenase/reductase (SDR) superfamily (Kavanagh KL et al. 2008), which 
constitutes one of the largest enzyme superfamilies with over 46,000 members 
present in sequence databases. The low sequence similarity among different 
members of this class suggests an early differentiation to enzymes with different 
catalytic properties (Persson B et al 2009). 
Typically, HSDHs are homodimers or homotetramers, each monomer 
consisting of about 250 residues with a core of -sheets sandwiched between α-
helices. The NAD(P)H cofactor binding domain is located at the N-terminus of 
the monomer, while the catalytic domain is located at its C-terminus. The 
contact area between monomers is mainly formed by two α helices (αE, αF) on 
each subunit. 
Despite a moderate sequence similarity, enzymes belonging to this family show  
similar secondary and tertiary structures. Moreover, they share common 
sequence motifs, such as those defining the cofactor binding site (TGxxxGxG, 
comprised in a Rossmann fold motif) and the active site, the latter represented 
for example in E. coli 7α-HSDH by the catalytic triad (S(x)12Y(x)3K) (Tanaka N 
et al. 1996, Tanaka N et al. 2001).  
HSDHs-catalyzed bile acids modifications have been studied using enzymes 
from different microbial sources. Good microbial producers of HSDHs may 
have evolved these peculiar enzymatic activities as detoxification mechanisms 
toward bile acids present in mammals intestines (Ridlon JM et al. 2006). The 
regulation of their expression varies depending on the enzyme and the source 
organism. Specifically, the expression can be either constitutive or induced by 
bile acids or growth phase dependent (Coleman JP et al. 1994). 
 
 
Hydroxysteroid dehydrogenases in bile acids transformation 
 
NAD(P)H-dependent HSDHs have been extensively used to catalyze the 
selective oxido-reduction of the hydroxy-keto groups of a variety of bile acids 
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For example, enzymes belonging to this class have been used as biocatalysts for 
redox reactions involving the hydroxy groups of cholic acid (CA) (Fig. 8) and 
the keto groups of dehydrocholic acid (DHCA, 3,7,12-trioxo-5β-cholan-24-oic 
acid, Fig. 9). 
Specifically, CA has been regiospecifically oxidized at each of the three 
possible positions (3α-OH, 7α-OH and 12α-OH, respectively) using either the 
3α-HSDH from P. testosteroni, the 7α-HSDH from E. coli, or the 12α-HSDH 
from Clostridium sp. (all these enzymes were commercially available at the 




Figure 8. Enzymatic oxidation of cholic acid 
 
Analogously, DHCA has been regio- and stereospecifically reduced at each of 
the three possible positions using 5 different HSDHs (the same used in cholic 
acid oxidation plus the commercially available 3β-HSDH from P. testosteroni 



































Figure 9. Enzymatic reduction of dehydrocholic acid. 
 
These reactions were carried out on a preparative scale, in potassium phosphate 
buffer. As reactions catalyzed by HSDHs are reversible, they were coupled to 
suitable cofactor regeneration systems to obtain complete conversions. Products 
were then recovered by acidic precipitation with ca. 80-90 % yields and purity 
over 97 % (Riva S et al.1986). 
Bioconversions catalyzed by HSDHs can be performed either with free enzymes 
or with enzymes immobilized on suitable supports. Enzyme immobilization 
usually improves enzyme stability, especially in those reactions carried out in 
the presence of organic solvents such as in biphasic systems. For example, 
cholic acid methyl ester was successfully oxidized to the corresponding 12-keto 
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in a biphasic system butyl acetate/potassium phosphate buffer (Carrea G et 
al.1988). 
 
More recently, HSDHs have been also employed in the preparation of a 39 
members array of cholic acid derivatives, thus demonstrating to be valuable 
biocatalysts also in the modification of non natural bile acids (Fig. 10) (Secundo 





Figure 10. Production of cholic acid derivatives by regioselective chemo-enzymatic 
oxidation-reduction steps and acylation steps. a: 3α-HSDH, MeOH/H
+
; b: 12α-HSDH; 
c: 7α-HSDH, MeOH/H
+
; d: DIBAH/THF; e: LiAIH4/THF; 
 
Moreover, the 7α-HSDH from B. fragilis has been successfully used for the 
stereoselective reduction of some aromatic and bulky aliphatic α-ketoesters and 






























































24 Hydroxysteroid dehydrogenases 
al 2011). HSDHs could be therefore considered as valuable biocatalysts even 
for the enantioselective reduction of non-steroidal carbonyl compounds. 
 
As this Thesis work was focused on the development and synthetic application 
of selected HSDH activities, i.e., 7α-HSDH, 12α-HSDH, and 7β-HSDH, the 




Up to now, various 7α-HSDHs (EC: 1.1.1.159) have been cloned, e.g., from 
Escherichia coli (Yoshimoto T et al. 1991), Bacteroides fragilis (Bennett M et 
al. 2003), Clostridium sordellii (Coleman JP et al. 1994) and Eubacterium sp. 
strain VPI 12708 (Baron S et al. 1991). The literature reports also the partial 
characterization of 7α-HSDHs from Bacteroides tetaiotamicron (Sherrod JA 
and Hylemon PB 1977) Clostridium perfringens (Macdonald IA et al. 1976), 
Clostridium absonum (Macdonald IA and Roach P 1981), Clostridium limosum 
(Sutherland JD and Williams CN 1985), Clostridium bifermentans (Sutherland 
JD et al. 1987), Clostridium baratii (Lepercq P et al. 2004),  Xanthomonas 
maltophilia (Pedrini P et al . 2006), and  Acinetobacter calcoaceticus lwoffii 
(Giovannini PP et al. 2008). Moreover, a search of primary structures of 7α-
HSDH in the UniProt Knowledgebase database (Swiss-Prot and TrEMBL, 
http://www.expasy.org/sprot/) results in more than 50 sequences codifying for 
putative 7α-HSDHs. 
To this list, the 7α-HSDH from C. absonum recently cloned and overexpressed 
in E. coli by our group (Paper III) must be added. 
 
The expression of these enzymes can be either constitutive or inducible  
(Coleman JP et al. 1994). In organisms such as E. coli and  Eubacterium sp. 
strain VPI 12708, 7α-HSDH is expressed constitutively (Prabha V et al. 1990,  
Macdonald IA et al. 1973, Franklund CV et al 1990, Baron S et al. 1991), while, 
for example, the 7α-HSDH from Clostridium limosum is induced by addition of 
primary bile acids or deoxycholic acid (DCA, 3α,12α-dihydroxy-5β-cholan-24-
oic acid) to the culture medium at the time of inoculation (Sutherland JD and 
Williams CN 1985). In Bacteroides spp., the production of 7α-HSDH activity is 
both growth phase dependent and bile acid inducible (Bennett M et al. 2003, 
Hylemon PB and Sherrod JA 1975, Sherrod JA and Hylemon PB 1977). In C. 
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phase in both the absence and the presence of bile acids in culture medium, but, 
in presence of bile acids, enzyme synthesis is improved of about 10 fold in the 
respect of that observed in uninduced cell (Coleman JP et al. 1994).  
 
The best characterized 7α-HSDH is the one from E. coli, whose crystal structure 
was solved at a resolution of 2.3 Å in a binary complex with NAD
+
 
(www.rcsb.org, PDB ID: 1AHH) and at 1.8 Å in the ternary complex with 
NADH and the reaction product 7-oxoglycochenodeoxycholic acid (PDB ID: 




Figure 11. Crystal structure of the 7α-HSDH from E. coli (PDB ID: 1AHH). 
 
Structural analyses indicate a possible involvement of the Tyr159 and Ser146 
residues, highly conserved in the SDR family proteins, in the interaction with 
the hydroxy groups of the substrate, whereas another highly conserved amino 
acid, Lys163, interacts via hydrogen bonds with the hydroxy groups in 2 'and 3' 










 binding to the active site in the binary complex of 7α-HSDHs 
(Tanaka N et al. 1996). 
 
On the basis of structural observations, a catalytic mechanism for the enzyme 
from E. coli that may be valid also for other 7α-HSDHs has been proposed (Fig. 
13) (Tanaka N et al. 1996, Tanabe T et al. 1998). 
In the first step, Lys163, lowering the pKa value of Tyr159, allows the 
deprotonation of the latter residue. The resulting deprotonated phenolic group 
forms a hydrogen bond with the hydroxyl group in position 7 of the substrate. 
The hydroxyl group of Ser146 may then form a hydrogen bond with the 
substrate, stabilizing its position. Subsequently, the deprotonated tyrosine 
residue acts as a base by extracting a hydrogen atom from the hydroxy group of 
the substrate. Concurrently, NAD
+
 accepts a hydrogen released from the 
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Figure 13.  Proposed catalytic mechanism for 7α-HSDH (Tanaka N et al. 1996). 
 
Recently, the crystal structure of the 7α-HSDH from Brucella melitensis has 
been solved at a resolution of 2.2 Å (PDB ID: 3GAF). 
 
Figure 14 shows the multiple alignment of sequences of some bacterial 7α-
HSDH (CLOSO, Clostridium sordellii ATCC 9714; EUBSP, Eubacterium sp. 
strain VPI 12708; BACFR, Bacteroides fragilis ATCC 25285; ECOLI, 
Escherichia coli strain HB101). As shown, 7α-HSDH primary structures do not 
exhibit a high level of identity, a greater conservation being observed in the N-
terminal region where a few amino acids necessary for catalysis, in particular 
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Figure 14. Multiple sequence alignment of some bacterial 7α-HSDH (CLOSO, 
Clostridium sordellii ATCC 9714; EUBSP; Eubacterium sp. strain VPI 12708;  
BACFR, Bacteroides fragilis ATCC 25285; ECOLI, Escherichia coli strain HB101). 
Blue arrows indicate the active site, whereas red arrows indicate amino acids supposed 
to be involved in cofactor binding. Amino acid underlined by red circles are involved in 
cofactor specificity. 
 
Among cloned or partially purified 7α-HSDHs, the only enzymes investigated 
up-to-now for synthetic applications are the one from E. coli (Riva S et al. 1986, 
Bovara R et al. 1993, Secundo F et al. 2003), that for a certain period has been 
commercially available from Sigma-Aldrich, the one from C. absonum (Bovara 
R et al. 1996),  that from Bacteroides fragilis (Zhu D et al. 2006, Liu Y et al. 
2011) and the enzyme from Acinetobacter calcoaceticus lwoffii (Giovannini PP 
et al. 2008).  
At least in non-operative conditions, the most robust biocatalyst among those 
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fact, this enzyme can be partially purified from the crude cell extract by a 
thermoprecipitation treatment without loss of activity (Bennet M et al. 2003). 
We have successfully used this enzyme in Paper I for the one-pot enzymatic 
synthesis of 12-ketoursodeoxycholic acid (12-KUDCA, 3α,7β-dihydroxy-12-
oxo-5β-cholan-24-oic acid) and in Paper II for the development of a new 




Much less information is available from the literature regarding 7β-HSDH (EC 
1.1.1.201) activities. The production of 7β-HSDH activity has been described 
for some clostridia, e.g., C. absonum, C. limosum, and C. baratii (Macdonald 
IA et al. 1981, Sutherland JD and Williams CN 1985, Lepercq P et al. 2004), 
and microorganisms belonging to the intestinal bacterial flora, e.g., 
Eubacterium aerofaciens and Peptostreptococcus productus (Hirano S and 
Masuda N 1982, Masuda N et al. 1983), and Ruminococcus sp. (Akao T et al. 
1987), or present in the soil such as Xanthomonas maltophilia (Pedrini P et al. 
2006). 7 -HSDH activity has been recently found also in rabbit liver 
microsomes (Shiotsuki H et al. 2006). 
 
Up to now, the unique cloned and overexpressed 7β-HSDH is the NADPH-
dependent enzyme from Collinsella aerofaciens (Liu L et al. 2011). Cloning of 
this gene has been achieved by cloning and expression in E. coli of nine genes 
coding for short-chain dehydrogenases displayed in the genome of C. 
aerofaciens. The only one capable to convert ursodeoxycholic acid into 7-keto-
lithocholic acid has then been identified.  
The evolutionary tree based on the alignment of C. aerofaciens 7β-HSDH with 
different HSDHs from either microbial or mammalian source (Fig. 15) shows 
that this prokaryotic 7β-HSDH is closer to the animal 11β-HSDH subgroup 
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Figure 15. Phylogenetic tree based on alignment of the C. aerofacens 7β-HSDH protein 
sequence, with other HSDHs (Liu L et al. 2011). 
 
The recombinant 7β-HSDH from C. aerofaciens has been purified and 
characterized. This enzyme shows a pH optimum of 9-10 in the oxidation of 
ursodeoxycholic acid and a pH optimum in the range of 4 to 6 in the reduction 
of 7-ketolithocholic acid (7KLCA). Maximum activity is reached at around 
30°C, whereas above 50°C both enzyme activity and stability are very low (Liu 
L et al. 2011). 
In the same period, our group has cloned and overexpressed in E. coli the 
NADPH-dependent 7β-HSDH from C.absonum (Paper III), the most used 7β-
HSDH for synthetic applications (Bovara R et al. 1996, Bovara R et al. 1993, 
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12α-Hydroxysteroid dehydrogenases 
 
12α-HSDHs (EC 1.1.1.176) are mainly found among clostridia, e.g., 
Clostridium perfringens (Macdonald IA et al. 1976), Clostridium leptum (Harris 
JN end Hylemon PB 1978), Eubacterium lentum (Macdonald IA et al. 1979a), 
and Clostridium group P strain C 48–50 (Macdonald IA et al. 1979b), and in 
Bacillus sphaericus (Tamasawa N et al. 1988). A 12α-HSDH activity has been 
recently described in Acinetobacter calcoaceticus lwoffii as well (Giovannini PP 
et al. 2008). These enzymes are constitutively expressed. 
Up to now, only the NADPH-dependent 12α-HSDH from Clostridium group P 
strain C 48–50 (Braun M et al. 1991) has been cloned and overexpressed in E. 
coli (Aigner A et al. 2009). The gene sequence has been obtained by sequencing 
the whole genome of the Clostridium strain and comparison with the N-terminal 
sequence of 12α-HSDH previously determined by Braun M et al. It has been 
found that this enzyme can exist in two forms, a long version (270 aa) and a N-
terminally truncated short version (258 aa). Moreover, substrate inhibition by 
cholic acid has been observed, these effects being limited by a single amino 
acidic mutation (37D12). Further attempts to change 12α-HSDH cofactor 
specificity from NADPH to NADH by substitutions G37D and R38L have not 
been successful. This enzyme is commercially available from ASA. 
 
The NADH dependent 12α-HSDH from B. sphaericus is commercially 
available from Genzyme, but there are no available information about its 
sequence. 
 
Hydroxysteroid dehydrogenases from Clostridium absonum 
 
Hydroxysteroid dehydrogenases produced by Clostridium absonum (Ca7α-
HSDH and Ca7β-HSDH) have been widely used for the modification of  bile 
acids (Bovara R et al. 1996, Bovara R et al. 1993, Riva S et al. 1986 and Paper 
I). 
These enzymes catalyze in vivo the epimerization of the 7α-OH of primary bile 
salts (Fig. 16). The resulting 7β-OH bile salts are less toxic to cell membranes 
compared to the 7α-OH primary bile salts because they are more hydrophilic 
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Figure 16. Epimerization of bile acids catalyzed by Ca7α- and Ca7β-HSDH. 
 
Clostridium absonum was isolated for the first time in the soil among some 
strains of "perfringens-like" clostridia (Nakamura N. et al. 1973), and it is a 
Gram-positive spore-forming anaerobic rod-shaped bacterium. 
The production of hydroxysteroid dehydrogenases by this microorganism has 
been extensively studied. Specifically, it has been shown that Ca7-HSDHs 
production has to be stimulated by inducers added to the culture medium. It is 
noteworthy that a low release of Ca7α-HSDH activity, but not of Ca7β-HSDH, 
was observed even in uninduced cells (Macdonald IA and Roach P 1981).  
Induction of Ca7α-HSDH and Ca7β-HSDH in cultures grown to stationary 
phase has been achieved by the addition of metabolizable bile salt inducers such 
as chenodeoxycholic acid (CDCA), 7-ketolithocholic acid (7KLCA),  and 
cholic acid (CA), or by the addition of non-metabolizable bile salts, such as 12-
ketochenodeoxycholic acid (12KCDCA, 3α,7α,12-oxo-5β-cholan-24-oic acid) 
and deoxycholic acid (DCA). 
The addition of metabolizable bile salt inducers has to be done 2.5-3 h after 
inoculation, because addition prior to or after this period markedly reduces the 
enzymes production. On the other hand, addition of non-metabolizable inducers 
could be done 2.5-3 h after inoculation or at earlier times with no significant 
difference in enzyme production levels. The best enzyme yield was achieved by 
adding CDCA (0.4 mM final concentration) at 2.5-3 h after inoculation. Studies 
on different volumes of growth showed that an increase in that volumes (i.e., 
from 100 mL to 1 L) resulted in yields higher (about 40% more), the best 
induction time in these conditions being at 1.5 h after inoculum (Macdonald IA 
and Sutherland JD 1983). 
It was also observed that the end product of CDCA epimerization, UDCA, was 
very effective in blocking the induction mediated by CDCA or DCA, while the 
end product of CA epimerization,  ursocholic acid (UCA, 3α,7β,12α-trihydroxy-
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1983). Moreover the addition of rifampicin at the same time with the inducer 
completely suppressed the expression of the two enzymes, thus suggesting a 
mechanism of induction based on the de novo synthesis of mRNA coding for 
proteins (Macdonald IA et al. 1983). 
The separation of Ca7β-HSDH and Ca7α-HSDH has been described by 
Macdonald and coworkers by a Procion red affinity chromatography. 
Subsequent purification of Ca7β-HSDH has been performed by a HPLC-TSK 
3000 gel filtration column. Approximately, a 35-fold purification of Ca7β-
HSDH was achieved, but SDS-PAGE analysis showed 6 major protein bands 
and unambiguous identification of the active band was not possible at that time 
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As previously stated, HSDHs are NAD(P)H-dependent enzymes. Due to their 
high cost, cofactors cannot be used in stoichiometric amounts in  oxidation or 
reduction reactions, especially in the case of industrial applications. 
Furthermore, as reactions catalyzed by HSDHs are reversible, the conversion of 
the substrate into the desired product is dependent on the equilibrium constants 
of the two opposite reactions. To overcome the above problems, a cofactor 
regeneration system can be exploited. In fact, it allows the use of catalytic 
amounts of the cofactor and, at the same time, it unbalances the system towards 
product formation by removing one of the products of the coupled reaction (i.e., 
the oxidized/reduced cofactor). 
 
Methods and strategies used in cofactor regeneration 
 
Generally speaking, no regeneration method is ideal and a combination of 
factors determines the best method for a certain application. From the point of 
view of the cost, the efficiency of such a procedure may be estimated by the 
molar amount of synthesized product per molar amount of consumed cofactor 
during the course of the complete reaction. This ratio is called total turnover 
number (TTN) (Leonida MD 2001). To make a process economically viable, 
the TTN should be in the order of hundreds up to thousands. The TTN rises 
steeply by decreasing cofactor concentration at the expense of the volumetric 
productivity, since the cofactor concentration gradually becomes limiting for the 
total reaction system (Wichmann R and Racki D 2005). At the same time, 
enzyme consumption (ecn), i.e., the amount of biocatalyst needed for producing 
a defined amount of product, must be considered as well. This parameter can be 
expressed also as productivity of the system, i.e., the amount of product that can 
be produced using a defined amount of biocatalyst. 
 
Several methods of cofactor regeneration have been studied: chemical, 
photochemical, electrochemical, biological and mixed methods (Leonida MD 
2001). Direct methods, such as chemical, photochemical and electrochemical 
methods, might be the simplest methods to regenerate cofactors but each of 
these has major disadvantages.  
Chemical methods, e.g., the direct oxidation or reduction of NAD(P)(H) by an 
inexpensive chemical reagent (Fig 17a), such as  dithionite, piridinium salts and 
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in the „70s , but they have been set aside because they are not efficient due to  
the instability of the reagents and slow reaction rates. Photochemical methods 
(Fig 17b), e.g., the direct oxidation/reduction of NAD(P)(H) by a 
photosensitizer/electron carrear system activated by irradiation, are more 
efficient than chemical methods, TTN being as high as 1125. However, they are 
still not advantageous because the photocatalysts could be photochemically 
degraded and possible side reactions could occur (Willner I and Mandler D 
1989). 
Electrochemical regeneration of NAD(P)
+
/NAD(P)H cofactors is an attractive 
alternative as it avoids the use of any additional reagent, it is simple and 
presents high enough regeneration numbers for preparative-scale applications 
(Wichmann R and Racki D 2005). Electrochemical strategies can be 
differentiated into two main approaches: (i) cofactors can be regenerated either 
directly on the surface of an electrode (Fig 17c) or (ii) by a mediator which is 
regenerated back on the surface of the electrode (Fig 17d). The first method has 
major drawbacks in NADH oxidation. In fact direct anodic oxidation of NADH 
at an inert electrode surface requires a relatively high overvoltage causing 
electrode fouling by strong absorption of NAD
+
 and the formation of 
enzymatically inactive forms of NAD
+
 (Gründig B et al. 1995). These 
limitations can be solved through the use of chemically modified electrodes that 
contain mediators which substantially lower the high overvoltage for NADH 
oxidation (method ii). To accelerate the electroanalytic oxidation of NADH, 
mediators such as o- or p-quinones, quinoid redox dyes such as indamines, 
phenazines, phenoxazines, phenothiazines, o- or p-phenylindiamines, 
aminophenols, flavin adenine dinucleotide (FAD), pyrroloquinoline quinone 
(PQQ), and metal ions like oxometalates, poly-metallophthalocyanines and 
ruthenium complexes (Hollmann F and Schmid A 2004, Gorton L 1986) have 
been investigated. Electrochemical reduction of NAD(P)
+ 
has been achieved by 
direct catodic electroreduction (TTN = 350 for the electrode direct NADH 
regeneration coupled to a glucose dehydrogenase/glucose system (Fassouane A 
et al 1990) and TTN = 220 for the direct electrode NADH regeneration coupled 
to a L-lactate dehydrogenase/L-lactate system (Biade AE et al. 1992)) or using 




































Figure 17. Examples of NAD(P)
+
 regeneration systems: a) chemical regeneration, b) 
photochemical regeneration through a reductive quenching mechanism, c) 
electrochemical regeneration d) electro-enzymatic regeneration. Enzp= enzyme 
catalyzing the desired reaction, S= photosensitizer, A= electron acceptor, Medred= 
Reduced form of the mediator, Medox= oxidized form of the mediator. 
 
As an alternative, biological methods, including both the use of whole cells and 
that of enzymes, have been investigated.   
In the case of whole cells, the enzyme that catalyzes the desired reaction can be 



























































38 HSDH-catalyzed biotransformations 
anyway regenerated by the systems present inside the cell (Fig. 18a). This 
system present major drawbacks, such as the difficulty of recovering the desired 
product, the need to use low substrate concentrations in large volumes due to 
low tolerance of cells to the substrate, low productivity and the possible 
formation of side products (Hollmann F et al. 2011). 
 
Instead, the use of isolated enzyme for cofactors regeneration may be very 
advantageous. Enzymatic regeneration can be achieved by two different ways 
(Fig. 18b and c). The first one is by means of the use of substrate-coupled 
reaction systems, in which one enzyme that uses both the reduced and oxidized 
forms of a cofactor is applied to catalyze both the desired synthesis of the 
product from one substrate and the cofactor regeneration reaction with a second 
substrate (Fig 18b). Since the same enzyme is required to catalyze two 
separated reactions simultaneously, it is usually difficult to achieve 
thermodynamically-favorite reaction conditions for both reactions in the same 
reaction medium.  
The second approach has been adapted for the majority of cofactor regeneration 
processes and consists in coupling the desired enzymatic reaction to another 
reaction catalyzed by a second enzyme that regenerate the cofactor (Fig 18c). 
These systems are very advantageous as offering greater efficiency and ease of 
use and they do not require any special equipment as in the case of 
photochemical or electrochemical methods. Moreover, if the coupled reaction is 
not reversible, the reaction of interest will be thermodynamically favored and 
can be driven towards the complete formation of the desired product.  
 
Among the cofactor regeneration systems mentioned herein, the enzymatic 
approach is particularly preferred for industrial processes due to its high 
selectivity and efficiency (Liu W and Wang P 2007). 
 































Figure 18. Examples of NAD(P)
+
 regeneration systems by biological methods: a) whole 
cell regeneration, b) substrate-coupled regeneration, c) enzyme-coupled regeneration. 




Cofactor regeneration by enzymatic systems 
Different enzymatic systems have been developed for cofactor recycling, 
depending both on the cofactor used (either NAD(H) or NADP(H)) and the 
direction of the reaction (oxidation or reduction). 
Concerning  the enzymatic regeneration of NAD(P)H, i.e. the reduced form of 
the cofactor that is used in reduction reactions (e.g., reduction of the 7-keto bile 
acid derivatives catalyzed by 7β-HSDH), the most commonly employed 
systems are the glucose/glucose dehydrogenase (GDH) (Fig. 19a) and 
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Figure 19. Enzymatic cofactor regeneration system for NAD(P)H regeneration. GDH= 
Glucose dehydrogenase, FDH= Formate dehydrogenase 
 
These systems are very advantageous, in fact both cosubstrates, glucose and 
formate, are inexpensive and both reactions are irreversible as glucose is 
oxidized to gluconolactone,  which hydrolyzes spontaneously, while formate is 
oxidized  into carbon dioxide that escapes into the environment. Moreover, in 
the case of formate dehydrogenase, formate/CO2 can be used as a buffering 
system, thus allowing to avoid the use of traditional buffers containing salts, 
such as phosphate and organic acids, that are considered powerful 
environmental pollutants and must be separated from the solutions before 
disposal of wastes. TTN obtained by using the formate/FDH system (up to 10
3
) 
are usually lower compared to those obtained by the glucose/GDH system (up 
to 10
6
) (van der Donk WA and Zhao H 2003). 
 
In the case of enzymatic regeneration of NAD(P)
+
, i.e. the oxidized form of the 
cofactor that is used in oxidation reactions (e.g., in the oxidation of 7α-OH bile 
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are α-ketoglutarate/glutamate dehydrogenase (GlDH) and acetone/alcohol 
dehydrogenase (ADH) for NAD(P)
+
 regeneration (Figure 20a and b) and  
pyruvate/lactate dehydrogenase (LDH) for NAD
+
 regeneration (Fig 20c) (van 






























Figure 20. Enzymatic cofactor regeneration system for NAD(P)
+
 regeneration. Gl-DH= 




Applications of cofactor regeneration systems in HSDH-catalyzed reactions 
 
As far as reduction reactions concerns, the glucose/GDH system has been 
mainly employed for cofactor regeneration on a lab scale (Bovara R et al 1996, 
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preliminary investigations have been carried out in the presence of the 
formate/formate dehydrogenase system.  
Various enzymatic regeneration systems have been instead applied to HSDHs-
catalyzed oxidations. 
In particular, the α-ketoglutarate/ GlDH and the lactate/LDH systems have been 
widely employed to regenerate the NADP
+ 
cofactor (Secundo F et al. 2003, 
Bovara R et al 1996, Bovara R et al. 1993, Riva S et al.1986, Carrea G et 
al.1984) and the NAD
+ 
cofactor (Giovannini PP et al 2008, Fossati E et al. 2006, 
Paper I), respectively. 
The use of LDH from rabbit muscles (commercially available from Sigma-
Aldrich) for NAD
+
 regeneration in the oxidation of cholic acid to 12-KCDCA 
catalyzed by the NADH-dependent 12α-HSDH from Bacillus sphaericus 
(Genzyme) has been recently patented. Experiments were carried out on a few 
ml scale, but using cholic acid concentrations up to 60 g/l (Fossati E et al. 
2006). In the same oxidation reaction, the commercially available GlDH from 
Proteus sp. was coupled to the NADPH-dependent 12α-HSDH from 
Clostridium sp. (from ASA) to regenerate NADP
+
 cofactor. After preliminary 
work, this reaction has been scaled-up to 15 L by the company  “Prodotti 
chimici e alimentari S.p.A.” (Basaluzzo (AL), Italy) in the „90s. To allow their 
reuse, both enzymes were immobilized on solid support. Cholic acid oxidation 
to 12-KCDCA acid at 40 g/l concentrations gave very promising results as 
quantitative yields for 50 cycles of reaction were achieved (unpublished 
results). Unfortunately the high cost of both the cosubstrate and the glutamate 
dehydrogenase made this system difficult to implement on an industrial 
production. 
 
In the search for efficient and cheap alternatives to the use of the α-
ketoglutarate/GlDH system for the in situ regeneration of NADP
+
 during the 
oxidation of cholic acid to 12-KCDCA acid, Fossati and coworkers explored the 
acetone/alcohol dehydrogenase (ADH) system. Because of the reversibility of 
the reduction reaction of the cosubstrate, a high concentration of acetone (more 
than 30 equivalents) was used to push the desired reaction to completion. The 
use of a large amount of acetone, however, turned out to be problematic because 
it compromised the stability of the enzymes. Moreover, despite the high 
concentration of the cosubstrate, the best reaction, carried out on a preparative 
scale (10 ml total volume, cholic acid concentration 40 g/l, acetone 
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not successful from an industrial point of view, unless TTN was up to 1,000 
(Fossati E et al. 2005). 
In 2011 this system was further investigated by Braun and coworkers who 
identified kinetic models for the simulation of batch processes for 12-KCDCA 
acid production integrated with the cofactor regeneration. Based on the 
identified process, model batch process optimization was performed in silico to 
minimize enzyme costs. Optimization allowed to identify best enzyme (12α-
HSDH from Clostridium sp.) concentrations and cofactor concentrations  in 
order to reach the maximal possible conversion of 100 mM cholic acid within 
48 h. Thanks to this tool, conversion of 100 mM cholic acid coupled to the 
acetone/ADH regeneration system was improved but complete conversion has 
not been achieved yet (Braun M et al. 2011). 
 
Recently, it was reported the use of activated ketones (e.g., methyl acetoacetate, 
chloroacetone) as cosubstrate in systems with cofactor recycling by ADH 
(Bisogno FR et al. 2009, Lavandera I et al. 2008). The advantage of these 
systems would be that the reduction reactions of activated ketones are 
practically irreversible, and therefore low amounts of cosubstrate, about 1.5 
equivalents, might be sufficient to push the reactions to which they are coupled 
to the complete oxidation. Patents have already been filed on these systems. For 
example, a system has been patented for the production of enantiomerically 
pure (S)-2-butanol by coupling the enantioselective oxidation of a racemic 
mixture of 2-butanol catalyzed by an ADH to the reduction of methyl 
acetoacetate (Pfaller R and Schneider C 2007). Inspired by these works, we 
have recently submitted a patent application for the exploitation of similar 
cofactor regeneration systems in different oxidation reactions of bile acids 
catalyzed by HSDHs (data not shown). 
 
Moreover, Aksu and coworkers have recently proposed a new cofactor 
regeneration method, coupling the electrochemical (Fig. 21) approach to the 
enzymatic approach (Aksu S et al. 2009). In this work, the reduced cofactor 
accepts electrons from a mediator, specifically 2,2‟-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid (ABTS), which is subsequently in situ 
regenerated  by a laccase, an oxidase widely used in textile industry. The 
terminal acceptor of electrons is oxygen that is reduced to water by the laccase. 
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This system was applied to the oxidation of several alcohols by ADHs, and 


















Figure 21.  Laccase/mediator system coupled to an ADH-catalyzed alcohol oxidation 
 
In Paper II we investigated the exploitation of a different mediator, Meldola‟s 
blue, in the oxidation of cholic acid to the corresponding 7-ketoderivative  
catalyzed by the 7α-HSDH from B.fragilis. A commercially available laccase 
from Trametes sp. was employed for mediator reoxidation. The system was 
successfully used also in a biphasic system where the methyl ester derivative of 
cholic acid had been dissolved in a suitable organic solvent.  
 
 
HSDHs in multienzymatic processes 
Multienzymatic  processes, which involve the use of two or more enzymes to 
catalyze reactions in a defined pathway, are becoming very attractive for the 
production of many compounds at an industrial level (Santacoloma PA et al. 
2011)  
The enzymatic reactions of a multienzymatic process can be performed either in 
two or more sequential steps that require the isolation of intermediates, or in a 
"one-pot" fashion, i.e., without the isolation of intermediates.  
In the first case, the first reaction of the process is set up, the product is isolated 
and added to a second reaction mixture to be converted into a second product.  
In one-pot processes instead the first reaction is set up, the product is not 
isolated, but, for example, other reagents and/or catalysts are subsequently 





45 HSDH-catalyzed biotransformations 
second product. A particular case of one-pot processes are the so-called 
"cascade" processes where all reagents and catalysts are present right from the 
beginning and the different enzymatic reactions proceed simultaneously. 
One-pot processes, by avoiding time-consuming or yield-reducing isolation and 
purification of the intermediates and minimizing the amounts of 
chemicals/solvents required, result effective in reducing operation time, costs 
and environmental impact. Moreover the whole process can be developed 
without having to optimize the individual steps. 
However, these processes are challenging as it is often difficult to find reaction 
conditions  that are suitable at the same time for the different reactions involved 
in the process. Due to the diverging reaction conditions, even much more 
challenging are those one-pot processes that involve concomitant oxidation and 
reduction steps (Schrittwieser JH et al. 2011). In fact, while oxidation and 
reduction reactions occur simultaneously in living cells with great efficiency, 
it‟s not easy to find conditions that allow to drive both reactions to completion 
in vitro.  
 
One of the first examples of sequential use of HSDHs for bile acid modification 
was from Bovara and coworkers. It reported the epimerization of bile acids and 
some of their derivatives by using the NADH dependent 7α-HSDH from E. coli 
and the NADPH-dependent 7β-HSDH partially purified from C. absonum 
(Bovara R et al. 1993) (Fig. 22). 
After the oxidative step the product was recovered and used for the subsequent 
reductive step. Reactions were coupled to a lactate/LDH system for NAD
+
 
regeneration and to a glucose/GDH system for NADPH regeneration. 
Epimerization of compounds from 1a to 7a were carried out at a substrate 
concentration of 12.5 mM in potassium phosphate buffer and the obtained yield 
was between 85 % and 94 %. Epimerization of compound 8a was performed in 



























































Figure 22. Epimerization of different bile acids and their derivatives 
 
The sequential use of the 7α-HSDH and 7β-HSDH from C. absonum for the  
/  inversion of C-7 hydroxyl of cholic acid was further investigated by the 
same group in order to obtain ursodeoxycholic acid directly from cholic acid 
(Bovara R et al 1996). 
In this case, cholic acid hydroxy groups at C-7 and C-12 were simultaneously 
oxidized  by the NADPH-dependent 7α-HSDH from C. absonum and the 
NADPH-dependent 12α-HSDH from Clostridium sp., respectively. Thus, 
through a stereo- and regioselective reduction catalyzed by the NADPH-
dependent 7β-HSDH from C. absonum, the previously isolated intermediate 
was transformed into the 12-ketoursodeoxycholic acid and then in 
ursodeoxycholic acid by a chemical reduction (Wolff-Kishner method) (Fig. 
23). In the first step oxidative reactions were coupled to a α-ketoglutarate/GlDH 
system for NADP
+
 regeneration, whereas in the second step the reductive 
reaction was coupled to a glucose/GDH system for NADPH regeneration. 
Reactions were carried out in aqueous solution and substrate concentration was 
12.5 mM. 
The 12α-HSDH used was commercially available from ASA, while 7α-HSDH 
was a crude extract from C. absonum and 7β-HSDH was partially purified from 
R1 R2 R3 X  
H H OH OH 1 
H H H OH 2 
H OH H OH 3 
OH H H OH 4 
H H OH NHCH2COOH 5 
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the same source. It is noteworthy that, according to this approach, preparations 
of crude 7α-HSDH and 12α-HSDH may be successfully used without any 
formation of byproducts, as these enzymes are highly regioselective and the 
preparations are free from enzyme contamination that could result in undesired 






























Figure 17. Chemoenzymatic synthesis of ursodeoxycholic acid 
 
On the contrary, the reduction reaction of the 7-oxo intermediate requires the 
use of a preparation of 7β-HSDH completely devoid of any 7α-HSDH activity, 
whose presence would lead to the formation of the corresponding 7α-hydroxy 
by-product (12-KCDCA). 
Reactions were quantitative and both the recovery of the final product (88 %) 
and its purity (>98 %) were satisfactory.  
 
This topic has been further investigated in Paper I by using a multienzymatic 
system with five different dehydrogenase activities and different reactions set-
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THESIS OVERVIEW 
 
Thanks to the exploitation of molecular biology techniques and to the advances 
of bioprocesses engineering, biocatalysis is making an increasingly important 
contribution to the development of sustainable industrial chemical processes. In 
fact, the number of available enzymes is continuously increasing, and directed 
evolution and  metabolic engineering technologies have led to the production of 
stable biocatalysts with customized activity and selectivity (Zaks A 2001). 
Moreover, enzymes belonging to different classes have been shown to be usable 
in a wide variety of applications and even in large-scale processes. This is 
particularly important in the pharmaceutical industry where high reaction 
selectivity on complex substrates is critical (Schmid A et al. 2001). 
 
Hydroxysteroid dehydrogenases (HSDHs) are NAD(P)H-dependent enzymes 
which belong to the SDR (short chain dehydrogenase/reductase) superfamily 
(Kavanagh KL et al. 2008). They are homotetrameric or homodimeric proteins, 
with a subunit molecular weight of approx. 30 kDa (Tanaka N et al. 1996), and 
catalyze the regio- and stereoselective oxidation/reduction of hydroxyl groups 
of steroids or bile acids in vivo (Ridlon JM et al. 2006). HSDHs from both 
mammalian and microbial sources have been identified, the latter having been 
widely employed in the selective modification of bile acids and their 
derivatives, even on preparative scale (Bovara R et al. 1996).  
 
Bile acids are amphiphilic steroidal molecules synthesized in the liver from 
cholesterol. In vivo, they play an important role in the digestion and adsorption 
of fats, fatty acids and lipid-soluble vitamins (Mukhopadhyay S and Maitra U 
2004).  
Bile acids and their derivatives are used in a variety of application, especially in 
the pharmaceutical field. In fact, they are currently used in the treatment of bile 
acid deficiencies, some liver diseases, and in the dissolution of cholesterol 
gallstones (Hofmann AF and Hagey LR 2008, Hofmann AF 2009). Moreover, 
bile acids are of interest for their ability of forming gels, thus making them 
potential materials for drug delivery (Mukhopadhyay S and Maitra U 2004). 
Additionally, their particular shape and amphiphilic properties make these 
compounds ideal as "building blocks" to be used as chiral artificial receptors 
and supramolecular hosts for molecular recognition (Tamminem J and 
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Among bile acids, ursodeoxycholic acid (UDCA; 3α,7β-dihydroxy-5β-cholan-
24-oic acid) is the most used in the pharmaceutical field, being indeed the first-
choice drug in the treatment of cholesterol gallstones and being also widely 
used for the treatment of other liver diseases, such as primary biliary cirrhosis 
(PBC) and primary sclerosis cholangitis (PSC) (Hofmann AF and Hagey LR 
2008).  
UDCA is currently synthesized from cholic acid ( 3α,7α,12α-trihydroxy-5β-
cholan-24-oic acid), a primary bile acid purified in huge amounts from bovine 
bile, by a ton-scale chemical synthesis, but this route is not completely 
satisfactory because of the lengthy protocol, the low yields and the use of 
polluting substances. The use of enzymes such as hydroxysteroid 
dehydrogenases could be a valid alternative in order to shorten the synthesis, 
increase the yield of UDCA, and limit the environmental impact of the 
production process.  
 
In the development of a biocatalytic process employing HSDHs, it must be 
taken into account that, as previously stated, HSDHs catalyzed reactions require  
NAD(P)H cofactors, which are very expensive. Therefore, especially in the case 
of industrial applications, a suitable cofactor regeneration system is necessary in 
order to use cofactors in catalytic amounts and no longer stoichiometrically. 
Furthermore, as reactions catalyzed by HSDHs are reversible, the conversion of 
the substrate into the desired product is dependent on the equilibrium constants 
of the two opposite reactions and the cofactor regeneration system helps  
unbalancing the system towards product formation. 
 
During this PhD work, the preparative-scale HSDHs-catalyzed one-pot 
enzymatic synthesis of 12-ketoursodeoxycholic acid (3 ,7 -dihydroxy-12-oxo-
5 -cholanoic acid), a key intermediate for the synthesis of ursodeoxycholic 
acid, from cholic acid, was first investigated. This goal has been achieved by 
using HSDHs with different cofactor specificity in oxidation and reduction 
reactions occurring in the same reaction mixture and properly driven by 
different cofactor regeneration systems. It was demonstrated that all the 
involved biocatalysts should be exclusively selective for the respective 
cofactors in order to perform this multienzymatic synthesis in a cascade process. 
In this specific case, the establishment of undesired reaction equilibria (likely 
due to a limited cofactor specificity of some of the enzymes used) leading to a 
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and purity, was overcome by uncoupling the oxidative and reductive 
biocatalysts. However, we may foresee that, thanks to the ongoing advances in 
biocatalysts engineering, new enzymes with exclusive NADPH or NADH-
specificity will become available in the near future (Paper I). 
 
As mentioned above, cofactor regeneration is a critical issue in HSDHs 
catalyzed reactions. Although NAD(P)H regeneration by enzymatic methods is 
quite satisfactory, NAD(P)
+ 
 regeneration is still challenging as the enzymatic 
methods reported in literature are actually limited by the high co-substrate costs 
or their reactivity. Moreover, exploitation of alternative electrochemical 
methods gave scarce results, mainly due to low total turnover numbers (TTN). 
In the second part of this PhD work we investigated a new NAD(P)
+ 
 




 redox mediator, Meldola‟s Blue (MB), 
used in low, catalytic amounts, accepts electrons from NAD(P)H and is thus 
converted into its reduced form. Subsequently, a laccase, an oxidase widely 





to H2O and concomitantly re-oxidizes NAD(P)H via MB at high turnover rates. 
This system was employed in the gram-scale 7α-hydroxysteroid 
dehydrogenase catalyzed oxidation of cholic acid into its 7-keto derivative. The 
system was tested both in aqueous and biphasic systems, and demonstrate to be 
cheap, very efficient, to have high stability, to tolerate solvents, and to be 
simple to employ (Paper II). 
 
Finally, it must be remarked that, while biocatalyzed transformations of bile 
acids by isolated HSDHs-catalyzed reactions have been widely investigated on 
a lab-scale, the lack of commercially available biocatalysts has generally limited 
the scale-up of the studied reactions to an industrial level. In the last part of this 
PhD work, my efforts were devoted to the cloning of the NADPH-dependent 
7α- and 7β-hydroxysteroid dehydrogenases (7α-HSDH and 7β-HSDH) from 
Clostridium absonum. The enzymes, once overexpressed in recombinant form 
in E. coli, have been submitted to a detailed kinetic and functional 
characterization in oxidoreductive reactions of industrial interest for the 
synthesis of bile acids derivatives. The results showed that both enzymes, in 
suitable bioconversion conditions, could be promising candidates for further 
applications in the epimerization reaction of bile acids at the C-7 position, e.g. 
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cholan-24-oic acid) or chenodeoxycholic acid (3α,7α,-diihydroxy-5β-cholan-24-
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